Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1180 participants.
Also called NCT05700266
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 1,180 participants
- Sponsor
- Registry
-
NCT05700266
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05700266. Randomized; single masking; primary purpose prevention. Start 2023-12-30 (anticipated); primary completion 2024-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
- Acronym
- AA-ICAS
- Condition
- Ischemic Stroke
- Condition
- Intracranial Atherosclerosis
- Condition
- Stenosis
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Aspirin
- Intervention (Other)
- Risk Factor Management in both arms
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Collaborator
- National Natural Science Foundation of China
Record details
- Record id
cardio:ct-nct05700266- Content hash
4ace47aee213b24a569768960638c689f47d21e24cbc79813b7ffbb39508d1e4